Investment Rating - The report maintains an "Outperform" rating for Super Hi International Holding [1][16]. Core Views - The company's profit-sharing strategy has led to short-term pressure on operating profit, but diversified brands are expected to drive new growth [1][16]. - The company achieved a revenue of USD 400 million in 1H25, a 7.0% year-on-year increase, and a net profit of USD 28.352 million, marking a turnaround from a loss in the previous year [5][15]. - The report highlights the strong growth in the takeaway business and the introduction of new business opportunities through strategic marketing collaborations [6][16]. Financial Performance Summary - Revenue projections for 2025-2027 have been slightly adjusted downwards by 2.3%/2.0%/1.9% to USD 860 million, USD 960 million, and USD 1.06 billion, respectively, with year-on-year growth rates of 10.2%, 11.5%, and 10.7% [10][16]. - The net profit attributable to shareholders is projected to be USD 40 million, USD 60 million, and USD 70 million for 2025-2027, reflecting year-on-year growth of 104.7%, 28.4%, and 21.9% [10][16]. - The operating profit margin for 1H25 was reported at 6.4%, down 2.3 percentage points year-on-year, consistent with the company's profit-sharing policy [5][15]. Revenue Breakdown - Restaurant operating revenue reached USD 380 million in 1H25, a 5.9% increase year-on-year, with significant contributions from Southeast Asia, East Asia, and North America [6][10]. - The takeaway business generated USD 7.738 million, showing a remarkable growth of 49.0% year-on-year, attributed to product optimization and strategic marketing [6][10]. - Other income amounted to USD 11.527 million, a 24.6% increase year-on-year, driven by the popularity of hot pot seasonings and the launch of a second brand under the "Red Pomegranate Plan" [6][10]. Cost Structure and Efficiency - In 1H25, the cost of raw materials and consumables increased by 8.1% to USD 130 million, accounting for 34.0% of revenue [8][10]. - Employee costs rose by 11.0% to USD 140 million, with an employee cost ratio of 35.3%, reflecting the expansion of the restaurant network and increased investment in employee welfare [8][10]. - The company is implementing measures to reduce costs and improve efficiency, which are expected to enhance profitability in the second half of 2025 [8][10].

Investment Rating - The report assigns an "Outperform" rating for Marubi Biotechnology, expecting the stock's total return over the next 12-18 months to exceed the return of its relevant broad market benchmark [20]. Core Insights - Marubi achieved operating revenue of 1.769 billion yuan in the first half of 2025, representing a year-on-year increase of 30.83%, driven by brand innovation, channel expansion, and operational efficiency improvements [2][8]. - The company's online channels generated 1.571 billion yuan in revenue during the first half of 2025, up 37.85% year-on-year, while offline channels saw a decline of 7.07% to 197 million yuan [2][8]. - Marubi's gross margin for the first half of 2025 was 74.6%, slightly down by 8 basis points year-on-year, attributed to optimization in product and sales structures [2][8]. Revenue and Growth - In Q2 2025, Marubi's revenue reached 923 million yuan, marking a 33.5% year-on-year growth [2][8]. - The Marubi brand generated 1.25 billion yuan in revenue in the first half of 2025, up 34.36% year-on-year, accounting for 70.72% of total revenue [2][8]. - The PASSIONAL LOVER brand achieved 516 million yuan in revenue, a 23.87% increase year-on-year, representing 29.22% of total revenue [2][8]. Cost and Profitability - Sales expenses in the first half of 2025 were 1 billion yuan, up 39.31% year-on-year, leading to a sales expense ratio of 56.5%, an increase of 3.4 percentage points [3][9]. - The net profit attributable to the parent company for the first half of 2025 was 186 million yuan, a 5.21% increase year-on-year, with a net profit margin of 10.5%, down 2.6 percentage points [3][9]. Product Development and Market Position - Marubi expanded its product range, particularly in eye care and anti-aging, with the Little Red Pen Eye Cream achieving a 150% year-on-year sales growth in the first half of 2025 [4][10]. - The Little Golden Needle Serum and other products maintained strong sales performance, with the Little Golden Needle Super Mask reaching a market share of 4.23% on TikTok [4][10]. Marketing and Sales Strategy - The company adopted an eight-account matrix operation model for self-broadcasting, achieving a penetration rate of 82% [5][11]. - Marubi's self-broadcasting business saw a 60% year-on-year increase in Q1 2025 and a 10% increase in Q2 2025 [5][11].

Investment Rating - The report maintains an "Outperform" rating for Anhui Yingjia Distillery with a target price revised down from RMB 66 to RMB 64 [2][6]. Core Views - The baijiu industry is currently undergoing a deep adjustment phase, and the company is implementing proactive measures to strengthen its competitive edge, particularly focusing on its Cave series [15]. - The company’s revenue for the first half of 2025 was RMB 3.16 billion, a decrease of 16.9% year-on-year, with a net profit of RMB 1.13 billion, down 18.2% year-on-year [11][3]. - The domestic market remains the company's mainstay, accounting for 79.1% of revenue in the first half of 2025, while out-of-province operations are facing significant contraction [12][4]. Financial Performance Summary - Revenue projections for 2025-2027 are estimated at RMB 6.10 billion, RMB 6.28 billion, and RMB 6.53 billion, respectively, with net profits of RMB 2.04 billion, RMB 2.11 billion, and RMB 2.22 billion [15][6]. - The gross margin for the second quarter of 2025 decreased by 2.6 percentage points year-on-year, indicating pressure on the product mix upgrade [13][5]. - The company’s diluted EPS is projected to be RMB 2.55 for 2025, with a P/E ratio of 25x for the same year [6][15]. Product and Market Analysis - Revenue from mid-to-high-end baijiu declined by 14.0% in the first half of 2025, while standard baijiu saw a decline of 32.5% [12][4]. - The company continues to push for a mid-to-high-end strategy, focusing on the Cave series as its core product line despite market pressures [12][4]. - The company is divesting from non-core assets, such as the Yingjia Business Hotel, to enhance its focus on the baijiu business [14][5].

Investment Rating - The report maintains an "Outperform" rating for Cirrus Aircraft (2507 HK) with a target price of HK$60.00, indicating expected relative performance above the market benchmark [2][15]. Core Insights - The company's performance significantly exceeded expectations, demonstrating robust profitability with a total revenue of USD 594 million in 1H2025, a year-on-year increase of 25.1%. Net profit reached USD 64.97 million, up 82.5% year-on-year, and the gross profit margin improved to 36.2% [3][12]. - Aircraft deliveries and service revenue are key growth drivers, with 350 aircraft delivered in 1H2025, a notable increase from 287 in the same period of 2024. The average selling price of SR2X aircraft rose to USD 1.14 million, reflecting a 9.6% year-on-year increase [4][13]. - The company has a strong order backlog of 1,056 aircraft as of June 30, 2025, indicating continued strong market demand and a deepened global presence across 36 countries [4][14]. Financial Summary - Revenue projections for 2025-2027 are USD 1.394 billion, USD 1.634 billion, and USD 1.904 billion, with corresponding net profits of USD 141 million, USD 176 million, and USD 206 million [5][15]. - The adjusted EBITDA margin for 1H2025 was 17.1%, up 3.7 percentage points year-on-year, highlighting improvements in cost control and operational efficiency [3][12].

Investment Rating - The report maintains an "Outperform" rating for Haidilao International Holding [2][14] Core Insights - Haidilao's short-term performance is under pressure, with the "Red Pomegranate Plan" gradually showing effects [1][4] - Revenue for 1H25 was RMB 20.7 billion, a decrease of 3.7% year-on-year, while net profit attributable to shareholders was RMB 1.76 billion, down 13.7% year-on-year [3][13] - The company plans to pay an interim dividend of HKD 0.338 per share, with a dividend payout ratio of 95% [3][14] Revenue Breakdown - Main brand revenue decreased by 9.0% to RMB 18.58 billion, with contributions from various city tiers: 17.0% from tier-one, 37.3% from tier-two, 41.8% from tier-three and below, and 3.9% from Hong Kong, Macau, and Taiwan [4][5] - Other restaurant revenue increased by 227.0% to RMB 0.6 billion, driven by the introduction of new dining brands under the "Red Pomegranate Plan" [4] - Takeout revenue grew by 59.6% to RMB 0.93 billion, attributed to the rapid growth of the "one-person meal" fast food segment [4] - Sales of condiments and ingredients rose by 55.0% to RMB 0.46 billion, while franchise revenue surged by 4684.0% to RMB 0.09 billion [4] Operational Metrics - As of 1H25, Haidilao operated 1,363 restaurants, including 1,322 self-operated and 41 franchised [5] - The average customer spending was RMB 97.9, a slight increase of 0.5% year-on-year, while the overall table turnover rate decreased by 9.5% to 3.8 times per day [5][6] - Same-store sales declined by 9.9% in 1H25, with tier-one and tier-two cities experiencing declines of 9.4% and 13.3%, respectively [5] Financial Forecasts - Revenue projections for 2025-2027 are RMB 44.45 billion, RMB 47.06 billion, and RMB 49.89 billion, representing year-on-year growth of 4.0%, 5.9%, and 6.0% respectively [8][14] - Net profit attributable to shareholders is forecasted to be RMB 4.63 billion, RMB 4.95 billion, and RMB 5.33 billion for the same period, with net profit margins of 10.4%, 10.5%, and 10.7% [8][14] - The valuation has been adjusted from 23x PE to 20x PE for 2025, leading to a target price of HKD 18.22 per share [8][14]

Investment Rating - The report maintains an "Outperform" rating for Hansoh Pharma with a target price of HKD 44.32, based on a current price of HKD 37.66 [2][7]. Core Insights - Hansoh Pharma's revenue for 1H25 reached CNY 7.4 billion, representing a year-on-year growth of 14%, with innovative drug sales contributing CNY 6.1 billion, up 22% year-on-year. Collaboration revenue was CNY 1.66 billion, an 18% increase year-on-year [3][12]. - The management has raised the full-year revenue guidance to high double digits, reflecting strong performance and expectations for continued growth [3][12]. Financial Performance - Revenue projections for FY25, FY26, and FY27 have been adjusted to CNY 14.7 billion, CNY 16.0 billion, and CNY 17.7 billion respectively, with net profit estimates of CNY 5.0 billion, CNY 5.1 billion, and CNY 5.7 billion [7][13]. - The gross profit margin (GPM) for 1H25 was reported at 91.1%, remaining stable compared to the previous year [3][12]. Segment Performance - The oncology segment generated CNY 4.5 billion, accounting for 61% of total revenue, driven by the strong sales of Aumolertinib, which received approvals for new indications [4][15]. - The anti-infection segment contributed CNY 740 million, while the central nervous system segment generated CNY 770 million, and the metabolism and other diseases segment accounted for CNY 1.4 billion [15][13]. Key Catalysts - Upcoming catalysts for Hansoh Pharma include the inclusion of Aumolertinib in the National Reimbursement Drug List (NRDL) and the anticipated approval of its combination with chemotherapy for NSCLC [4][15]. - The company has received approximately CNY 850 million in milestone revenue, exceeding previous management guidance, indicating a potential for sustainable revenue growth from future milestones [15][13].

Investment Rating - The report assigns an "Outperform" rating to multiple companies in the consumer staples sector, including Moutai, Wuliangye, Luzhou Laojiao, and others, indicating a positive outlook for these stocks [1]. Core Insights - The report highlights a general decline in wholesale prices across most categories of consumer staples, particularly in the baijiu segment, with significant price drops noted for Moutai and Wuliangye [3][32]. - It emphasizes the structural opportunities arising from policy catalysis in the consumer staples sector, suggesting that investors should focus on these potential growth areas [3]. Summary by Sections Price Trends - Recent wholesale prices for Moutai show a decrease, with Feitian Moutai (case) priced at 1845 yuan, down 70 yuan from the previous month, and a year-to-date decline of 395 yuan [32]. - Wuliangye's eighth-generation price remains stable at 920 yuan, with no change since the beginning of the year [32]. - The report notes that the prices of various baijiu brands have shown a downward trend, with year-on-year declines for many products [4][32]. Discount Trends - Discounts on mass-market consumer goods have widened, particularly for liquid milk, soft drinks, infant formula, seasonings, and beer, indicating a shift in consumer purchasing behavior [19][30]. - The average discount rate for liquid milk decreased from 79.1% to 74.8%, while soft drinks saw a drop from 91.8% to 88.3% [19][30]. - The report provides a detailed overview of discount rates across various categories, showing a general trend of increasing discounts in the consumer staples market [20][21].

Investment Rating - The report suggests a focus on companies such as Howmet Aerospace, BAE Systems, and Safran as potential investment opportunities in the aerospace and defense sector [5]. Core Insights - The successful launch of China's "Guowang" constellation on August 26, 2025, marks a significant acceleration in its national satellite internet project, aiming to deploy approximately 1,300 satellites by 2029 and a long-term goal of around 13,000 satellites [1][9]. - This initiative reflects China's strategy to establish a sovereign satellite communications system, ensuring technological sovereignty and enhancing global competitiveness [1][10]. - The emergence of a strong, state-backed competitor in low-Earth orbit satellite communications is expected to fundamentally alter the market landscape, previously dominated by U.S. companies like SpaceX's Starlink [3][11]. Summary by Sections Event Overview - The launch of the "Guowang" constellation is part of a long-term national strategy, signaling a robust entry into the low-Earth orbit satellite communications sector [2][10]. Market Implications - The accelerated deployment of China's satellite constellation is likely to trigger a competitive response in Western countries, prompting increased investment in domestic satellite constellations to maintain strategic advantages [3][11]. - This competition may evolve into a government-backed race for satellite constellations, leading to more certain long-term demand across the entire supply chain [3][12]. Industry Impact - The competition will create multi-year project pipelines and capital expenditures for Western contractors, with a strong demand for higher-performance satellites and related technologies [3][12][13]. - Western A&D companies may benefit from increased government support to ensure supply chain security and technological leadership in response to the new competitive landscape [4][13].

Investment Rating - The report maintains an "OUTPERFORM" rating for Sichuan Kelun-Biotech with a target price of HK$519.20 [2][3]. Core Views - The company is expected to see robust growth driven by domestic commercialization and global collaborations, particularly in the ADC (Antibody-Drug Conjugate) sector [7][8]. - The drug Sac-TMT is anticipated to become a significant partner to Keytruda, with potential peak sales reaching USD 15-20 billion [8][13]. - The revenue forecasts for FY25-27 have been revised upwards, with expected revenues of RMB 20.6 billion, RMB 28.0 billion, and RMB 48.3 billion respectively [3][7]. Summary by Sections Financial Projections - Revenue for FY24 is projected at RMB 1.933 billion, increasing to RMB 2.056 billion in FY25, RMB 2.798 billion in FY26, and RMB 4.833 billion in FY27, reflecting growth rates of 25%, 6%, 36%, and 73% respectively [2][3]. - Net profit is expected to improve from a loss of RMB 267 million in FY24 to a profit of RMB 879 million by FY27 [2][3]. Product Pipeline and Market Position - The company has commercialized three products in China and has one product awaiting NDA approval, with over ten products in early clinical stages [7][8]. - The ADC platform is positioned as a leader in the domestic biopharmaceutical sector, with significant collaborations with Merck in the ADC field [7][8]. Clinical Development and Global Expansion - Sac-TMT has initiated 14 overseas clinical trials covering various cancers, with a potential patient population of 200,000 to 300,000 [8][20]. - The drug is expected to show strong sales growth in conjunction with Keytruda, particularly in lung cancer and breast cancer indications [8][13]. Competitive Landscape - Sac-TMT is positioned to become a best-in-class TROP2 ADC, with ongoing clinical trials expected to validate its efficacy against existing therapies [13][35]. - The report highlights the competitive advantages of Sac-TMT over other ADCs in the market, particularly in addressing unmet needs in NSCLC and breast cancer [24][35].

Investment Rating - The report maintains a cautious investment stance on the consumer sector, particularly highlighting concerns over low-income consumer behavior and the impact of tariffs on essential goods [4]. Core Insights - The consumer confidence index has declined, with the Michigan Consumer Sentiment Index dropping to 58.6 in August from 61.7 in July, marking a 5% decrease and falling below market expectations [7]. - Retail sales data remains resilient, with July retail sales reaching $726.28 billion, a year-on-year increase of 3.9% [7]. - Inflation remains moderate, with the Consumer Price Index (CPI) rising 0.2% month-on-month and 2.7% year-on-year in July, slightly below expectations [9]. - Employment data shows a significant downward revision, with only 73,000 non-farm jobs added in July, far below the expected 110,000 [14]. Macroeconomic Overview - Consumer confidence has weakened, with inflation concerns rising. The short-term inflation expectation increased from 4.5% to 4.9% [7]. - Retail sales growth is dependent on policy incentives and promotional activities, while consumer concerns about prices and unemployment persist [7]. - The CPI is influenced by declining energy prices and initial tariff effects, with core CPI reaching 3.1%, the highest this year [9]. Essential Consumption Insights - Beverage sales show marginal weakness, while tobacco data has rebounded. Alcohol and dairy sectors continue to exhibit weakness [27]. - Alcohol retail sales in June were $5.95 billion, down 3.3% year-on-year, indicating limited resilience in sales [27]. - Dairy product shipments totaled $13.61 billion in June, with a year-on-year increase of 1.6%, reflecting a relatively flat performance [31]. - Tobacco shipments reached $6.05 billion in June, up 7.3% year-on-year, with a CPI increase of 6.5% [33]. Discretionary Consumption Insights - Restaurant and department store sales show marginal weakness, while clothing sales have improved [35]. - Restaurant retail sales in July were $98.3 billion, a year-on-year increase of 5.6%, but a month-on-month decline of 0.4% [35]. - Department store sales reached $77.39 billion in July, up 2.3% year-on-year, but still below overall retail sales growth [38]. - Clothing retail sales in July were $26.63 billion, up 5.0% year-on-year, with expectations of price increases due to tariffs [40]. Market Performance and Valuation - The discretionary consumption sector performed well, with an 8.2% increase, while the essential consumption sector declined by 1.7% [4]. - The essential consumption ETF saw a net inflow of $120 million, while the non-essential consumption ETF experienced a net outflow of $650 million [4]. - The median valuation for leading food and beverage companies in the U.S. stock market was 24x at the end of July, indicating a relatively high valuation level [4].